SPR Therapeutics


Series C
Capital Raise
December 2017

Company Overview

  • SPR Therapeutics has developed a novel, minimally-invasive peripheral nerve stimulation (PNS) therapy platform that addresses a critical unmet need for chronic and post-operative/acute pain
  • Alleviating the need for opioids and surgery, the SPRINT™ PNS System is the least-invasive and lowest-cost neurostimulation option that allows the large base of interventional pain management physicians to adopt this non-destructive therapy early in the treatment continuum

Value Provided by Frontcourt

  • Engaged and acted as Financial Advisor
  • Created and implemented Corporate Public Relations strategy
  • Engaged and introduced leading pain management Key Industry thought leaders
  • Engaged and introduced key potential customer contacts
  • Frontcourt identified and structured an oversubscribed Series C offering
  • Participation from Frontcourt Ventures, Frontcourt individual LP’s and several independent value-added institutional investors
  • Identified and introduced value-added Industry executives and Board Members

We want to work with you

We can't wait to meet you. Hear your story. Connect.

Contact Us